BCL2L1 and plasma cell myeloma: The results showed that the downregulation of BCL-XL expression might not account for the synergistic anti-myeloma effect of the two drugs, since combined treatment with chidamide and venetoclax still induced a markedly higher rate of apoptosis than chidamide or venetoclax monotherapy in BCL-XL knockdown cells and the knockdown of BCL-XL did not sensitize MM1.S and U266 cells to chidamide or venetoclax monotherapy or combination therapy (Fig. 5G).